« Back
Home /
BMS-345541 (hydrochloride)

BMS-345541 (hydrochloride)

Item no.	HY-10518-50mg
Manufacturer	MedChem Express
CASRN	547757-23-3
Amount	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 50 mg 5 mg
Category	Oncology Neuroscience Neural Lineage Markers Neuroinflammation Metabolism Diabetes Glucose Homeostasis Inhibitors & Compound Libraries Small Molecules By Organ Skin Cancer Cytoskeleton Markers
Type	Inhibitors
Specific against	other
Purity	99.90
Citations	[1]Burke JR, et al. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem, 2003, 278(3), 1450-1456.\|[2]Yang J, et al. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res, 2006, 12(3 Pt 1), 950-960.\|[3]MacMaster JF, et al. An inhibitor of IkappaB kinase, BMS-345541, blocks endothelial cell adhesion molecule expression and reduces the severity of dextran sulfate sodium-induced colitis in mice. Inflamm Res, 2003, 52(12), 508-511. Cancer Cell. 2015 Mar 9;27(3):409-25. \|Cell Res. 2019 Mar;29(3):193-205. \|Cell Syst. 2018 Apr 25;6(4):424-443.e7.\|Harvard Medical School LINCS LIBRARY\|J Mol Med. 2020 Oct;98(10):1479-1491.\|Aging (Albany NY). 2021 Aug 10;13(15):19088-19107.\|Am J Hematol. 2024 Apr 22.\|Am J Physiol Endocrinol Metab. 2021 Feb 15.\|Biochem Biophys Res Commun. 2023 Nov 5, 680, Pages 127-134.\|Biomed Pharmacother. 2020 Jul;127:110116.\|Cancer Metab. 2024 Jul 8;12(1):20.\|EMBO Mol Med. 2025 Feb 19.\|Front Microbiol. 2021 Feb 2;12:607451.\|Int Immunopharmacol. 2021 Oct 26;101(Pt A):108264.\|iScience. 2024 May 16.\|J Dent Res. 2019 Jul;98(8):896-903.\|J Pharmacol Sci. 2023 Dec, 153(4), 188-196.\|J Vet Sci. 2023 Sep 4;24(5):e72.\|J Virol. 2019 Nov 26;93(24):e01499-19.\|Nat Metab. 2023 Mar 6.\|PLoS Comput Biol. 2020 Jun 26;16(6):e1007901.\|Research Square Print. October 27th, 2022.\|Sci Transl Med. 2021 Jan 27;13(578):eaba7308.
Smiles	CC1=CN=C2C(NCCN)=NC3=CC=C(C=C3N21)C.Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	547757-23-3
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	IKK
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	291.78
Product Description	BMS-345541 hydrochloride is a selective inhibitor of the catalytic subunits of IKK (IKK-2 IC50=0.3 μM, IKK-1 IC50=4 μM). BMS-345541 binds at an allosteric site of IKK.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 20 mg/mL (ultrasonic)\|H2O: 50 mg/mL (ultrasonic)
Manufacturer - Pathway	NF-κB
Isoform	IKK-α; IKK-β
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10518-50mg-safety-datasheet.pdf